Global /United States /Healthcare /Drug Manufacturers - General /SLNO

Soleno Therapeutics, Inc.

SLNO

• NASDAQ: SLNO • Delayed

52.78USD 0%

As of 13 June 2026, Soleno Therapeutics, Inc. has a market cap of $2.73B USD, ranking #5798 globally and #1516 in the United States. It ranks #459 in the Healthcare sector, and #182 in the Drug Manufacturers - General industry.

Global Rank

5798

Country Rank

1516

Sector Rank

459

Industry Rank

182

Key Stats

Market Cap

$2.73BUSD

Enterprise Value

$2.28BUSD

Revenue (TTM)

$190.41MUSD

EBITDA (TTM)

$16.97MUSD

Net Income (TTM)

$20.48MUSD

EBITDA Margin

8.9%

Profit Margin

11%

PE Ratio

135.4

Forward PE

13.4

PS Ratio

14.3

PB Ratio

6.1

EV/EBITDA

134.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Anish Bhatnagar open_in_new

Employees

182

Founded

1999

IPO

13 Nov 2014

Website

soleno.life open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	0.1%	76%	27%	-23%	14%	-28%	1K%	181%

News

SLNO Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	SLNO Soleno Therapeutics Inc ISIN: US8342033094 Shares Out.: Shares Outstanding: 52.12M¹ Shares Float: 50.009M² TV: TradingView: NASDAQ: SLNO SA: Stock Analysis: NASDAQ: SLNO YF: Yahoo Finance: SLNO GF: Google Finance: NASDAQ: SLNO NQ: NASDAQ: SLNO BA: Barron's: SLNO MS: Morningstar: XNAS: SLNO	52.78 USD	TV: TradingView: NASDAQ: SLNO SA: Stock Analysis: NASDAQ: SLNO YF: Yahoo Finance: SLNO GF: Google Finance: NASDAQ: SLNO NQ: NASDAQ: SLNO BA: Barron's: SLNO MS: Morningstar: XNAS: SLNO
Borsa Italiana (MIL / BIT) MIC: XMIL	1SLNO Soleno Therapeutics Inc ISIN: US8342033094 TV: TradingView: MIL: 1SLNO SA: Stock Analysis: BIT: 1SLNO YF: Yahoo Finance: 1SLNO.MI GF: Google Finance: BIT: 1SLNO BA: Barron's: 1SLNO MS: Morningstar: XMIL: 1SLNO	45.58 EUR	TV: TradingView: MIL: 1SLNO SA: Stock Analysis: BIT: 1SLNO YF: Yahoo Finance: 1SLNO.MI GF: Google Finance: BIT: 1SLNO BA: Barron's: 1SLNO MS: Morningstar: XMIL: 1SLNO

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Soleno Therapeutics, Inc.

Soleno Therapeutics, Inc., biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is VYKAT XR, an extended-release tablets for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 28K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 20K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 13K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 10K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 5K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 4K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 12K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 10K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 10K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 7K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 4K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 4K%	14.6	United Kingdom

chevron_leftBack